Tokyo District Court, 2022 (Wa) 9716 [5-Aminolevulinic Acid Phosphate] <Shibata>
Updated: 1 hour ago
Article information
Article type: Case note
Classification: Patents
Issues: Claim interpretation, Novelty, Enablement, Doctrine of equivalents
First published on this website: 2026-11-20
Case numbers: 2022 (Wa) 9716 / 2003 (Ne) 3034
Display and classification checked: 2026-11-21
Article date: 2023-08-15
Tokyo District Court, 2022 (Wa) 9716 [5-Aminolevulinic Acid Phosphate] <Shibata> July 28, 2023
<Whether the claim limitations are met>
An invention of a novel substance: the claim is satisfied even without isolation and even at low concentration!!
Cf. Tokyo High Court, 2003 (Ne) 3034 <Shinohara>
[Process for Producing a Morphologically Homogeneous Form of a Thiazole Derivative]
* The mixture was prior art ⇒ The invention was a particular crystalline form!
"... Taking the prosecution history into account ... on the premise that a mixture of Form A ... and Form B ... existed ... it was limited to the particular crystalline form ‘Form B famotidine.’"
<Invalidity>
Novelty upheld: The reasoning is the same as in Intellectual Property High Court, 2022 (Gyo-Ke) 10091 [5-Aminolevulinic Acid Phosphate] <Shoji>, March 22, 2023
⇒ Even if a substance's name appears in a cited reference, disclosure is not recognized unless a person skilled in the art is found able to carry it out without exercising creative ability through thought, trial and error, or similar efforts.
⇒ The cited reference and other materials, together with common general technical knowledge, must have enabled production of ‘the phosphate,’ at least as part of a mixture.
★ At the filing date, the phosphate was difficult to produce!!
⇒ This connects with the third requirement of the doctrine of equivalents!!
<Some observations>
In its analysis of whether the claim limitations were met, this judgment held that the accused products satisfied the claim merely by containing the invention's 5-aminolevulinic acid phosphate in a mixture, even though it was not isolated. At the beginning of its novelty analysis, the judgment stated, ‘It is not recognized that technology for obtaining 5-aminolevulinic acid in its free form was well known at the priority date.’ One might hastily think this contradicts the infringement analysis. Reading further, however, it stated that ‘it cannot be assessed that the compound 5-aminolevulinic acid phosphate was produced.’ The lack-of-novelty argument was rejected because a person skilled in the art was not found to have been able to produce the novel compound without exercising creative ability through thought, trial and error, or similar efforts at the priority date. In this case, the cited reference stated the substance's name (the invention's 5-aminolevulinic acid phosphate), but because a person skilled in the art was not found to have been able to carry it out without exercising creative ability through thought, trial and error, or similar efforts, disclosure in the reference was not recognized, or its eligibility as a cited invention was denied. Not only this judgment but many court decisions require that, for a cited invention to be recognized as disclosed in a reference, a person skilled in the art must be able to carry out the relevant configuration and other features without exercising creative ability through thought, trial and error, or similar efforts, based on the reference's disclosure and common general technical knowledge. Applied here, it was necessary that a person skilled in the art could produce ‘5-aminolevulinic acid phosphate’ at least as part of a mixture without exercising creative ability through thought, trial and error, or similar efforts. However, the state of the art at the priority date made it difficult not only to isolate the substance but also to produce 5-aminolevulinic acid ‘phosphate’ even in a mixture. The lack-of-novelty argument was therefore rejected despite the name appearing in the reference. One should always keep in mind the possible counterargument, as in this case, that even if a published document names the compound of the invention, a person skilled in the art could not produce it without exercising creative ability through thought, trial and error, or similar efforts at the state of the art at the priority date. Thus there is no contradiction between this judgment's infringement and invalidity analyses. At the filing date (priority date), the skilled person could not produce the compound without exercising creative ability through thought, trial and error, or similar efforts, whereas infringement was found because the accused products actually contained the claimed compound. This was not a finding that the specification’s disclosure caused manufacture to become possible. Enablement and support are separate issues. This situation has something in common with the third requirement of the doctrine of equivalents. The third requirement concerns whether the substitution would have been easy at the time of manufacture or other relevant acts. The fourth concerns whether the accused product or process was identical to, or readily inferable from, the prior art at filing. The different assessment dates offer a point of comparison, but the subjects of the two inquiries also differ; equivalence does not require that a single form of ease change over time. However, under the general approach adopted by this and many other judgments, even where a published reference names the compound, novelty and inventive step are not immediately negated unless it can be proved that the skilled person could produce the compound without exercising creative ability through thought, trial and error, or similar efforts at the state of the art at the filing date (priority date). The first person to succeed in producing a particular compound within a mixture may therefore obtain a product patent without isolating it, provided the other patentability requirements are also met, and may enforce that patent against persons working mixtures containing the compound. Here, 5-aminolevulinic acid was known, the novel substance was its ‘phosphate,’ and the compound ‘5-aminolevulinic acid phosphate’ itself was expressly named in published literature. Where the invention's technical significance lies in first enabling manufacture of the ‘phosphate,’ there is room to debate whether granting a product patent rather than a manufacturing-process patent strikes the right balance, and whether enforcement should be allowed against alleged infringers who produce or otherwise deal in mixtures containing the compound through processes other than the one actually invented. This issue also relates to IP High Court, 2007 (Gyo-Ke) No. 10378 [Crystalline Azithromycin Dihydrate]. That judgment asked whether a skilled person could understand the cited reference as describing a product identical to the invention on the basis of the common general technical knowledge and state of the art before the priority date. It did not treat the mere factual existence of an identical product before that date as decisive. The court held that the cited reference did not disclose the invention’s configuration, without deciding whether the crystal described in that reference could objectively be identified as azithromycin dihydrate. Taking that reasoning as a starting point, one can consider the hypothetical case in which the substance was not actually new but the inventor first recognized its presence. Whether granting a product patent in that situation strikes the right balance, and whether enforcement should be allowed against alleged infringers continuing to manufacture and sell the prior art—products actually containing the substance although no one had noticed it—are matters of debate in relation to the public domain.
(Extract from the court's reasoning)
<Whether the claim limitations are met> ⇒ Because this is an invention of a novel substance, the claim is satisfied even without isolation and even at low concentration!!
The defendant argues that its products do not fall within the technical scope of the invention because they are amino-acid-containing foods, the 5-aminolevulinic acid phosphate is not isolated, and its purity is low. However, the invention concerns a novel chemical substance. Its purpose is to provide 5-aminolevulinic acid phosphate as a novel chemical substance, not to increase its purity. If it is the invention's 5-aminolevulinic acid phosphate, it can be said to produce the invention's effects even if it is not isolated and even if its concentration in the containing product is not high.
<Invalidity (novelty)>
⇒ Novelty upheld (same reasoning as Intellectual Property High Court, 2022 (Gyo-Ke) 10091 <Shoji>)
... References Otsu 16–18 cannot be said to disclose technology for obtaining 5-aminolevulinic acid in its free form. In addition, ... the cited reference states that ‘5-ALA is ... chemically extremely unstable’ and that ‘only acidic aqueous solutions of 5-ALA HCl are shown to be sufficiently stable’ ([0007]). Considering also that these matters were common general technical knowledge at the priority date, technology for obtaining 5-aminolevulinic acid in its free form cannot be recognized as well known at that date.
On this point, the plaintiff argues that production of 5-aminolevulinic acid phosphate does not require 5-ALA to have been extracted as a substance, and that it may remain mixed with culture-medium components and the like in a fermentation liquid. However, at the priority date, adding acid or base to a mixture containing various components was not recognized as common general technical knowledge for producing a salt compound. A skilled person encountering the cited reference at that date therefore could not, without exercising creative ability such as thought or trial and error, have found the method of adding phosphoric acid to fermentation liquid containing 5-aminolevulinic acid mixed with medium components (or adding that fermentation liquid to a phosphoric acid solution) as a method for producing the compound 5-aminolevulinic acid phosphate. Furthermore, ... as is also evident from Otsu 17's description of yeast extract, tryptone, and other ingredients in the medium, fermentation liquid mixed with medium components contains various ions as impurities. Even if phosphoric acid is added to such liquid, it cannot be assessed that the compound 5-aminolevulinic acid phosphate has been produced through neutralization of equal molar amounts of acid and base. ... There are no other circumstances indicating that a skilled person at the priority date could have found a method of producing or otherwise obtaining 5-ALA phosphate. ...
Accordingly, a skilled person encountering the cited reference at the priority date could not, without exercising creative ability such as thought or trial and error, have found a method of producing or otherwise obtaining 5-ALA phosphate based on the common general technical knowledge at that date. Thus 5-ALA phosphate cannot be identified as a cited invention from that reference.
Update history
This history records changes actually made to publication, display, and classification on this website.
20 November 2026: First published on this website.
21 November 2026: Article type, classification, issues, related articles, consultation links, and SEO were maintained. The original text was not changed.
Comments